Metabolic fingerprints of altered brain growth in a Rett syndrome mouse model: a 31P and 1H MRS study of tissue extracts

A. Viola1, V. Saywell2,3, L. Villard2,3, P. J. Cozzone1, and N. W. Lutz1

1Centre de Résonance Magnétique Biologique et Médicale (CRMBM), UMR CNRS n°6612, Faculté de Médecine de Marseille, Université de la Méditerranée, Marseille, France, 2INSERM U491, School of Medicine, Marseille, France, 3INSERM U491, Université de la Méditerranée, Marseille, France

Introduction

Rett syndrome (RS) is the leading cause of profound mental retardation of genetic origin in girls [1]. In most cases, RS is caused by mutations or deletions in the MECP2 gene [2]. Several behavioral, neuroanatomical and neurochemical features are consistently associated with RS. Among these are decelerating head growth in childhood, resulting in microcephaly, and cerebellar atrophy in adult RS patients [3]. Phospholipid (PL) metabolism plays an essential role in cell growth since PL form the matrix of cell membranes. We therefore performed a comprehensive phospholipidomic study in an RS mouse model with Mecp2 deletion to analyze metabolic processes underlying reduced brain size.

Methods

Experiments were performed using the mouse model strain B6.129P2(C)-Mecp2tm1-1Bird as described previously [4]. Freeze-clamped brains were extracted with methanol/chloroform/water. The resulting aqueous and organic phases underwent 1H and 31P MRS, respectively. Spectra were acquired on an AVANCE 400 spectrometer (Bruker, Wissembourg), using acquisition parameters described previously [5]. Spectra were referenced using trimethylsilyl tetradeuteropropionate and methylene diphosphonate as external standards, respectively, and evaluated with Bruker’s deconvolution software (Topspin 1.3). The metabolite concentrations obtained, as well as selected metabolite ratios, were statistically analyzed employing the Mann-Whitney U test (n=4 for each mutants and controls), using Statview 5.0.1 (SAS, Cary, NC, USA).

Results

Figure 1 shows a typical 31P MR spectrum representing PL from the Mecp2-null brain (lower spectrum magnified). PtdC, phosphatidylcholine; PtdI, phosphatidylinositol; SM, sphingomyelin; PtdS, phosphatidylserine; PtdE, phosphatidylethanolamine; PtdE_plasm, ethanolamine plasmalogen; CL, cardiolipin; AAPtdC, alkyl-acyl phosphatidylcholine; AAPtdE, alkyl-acyl phosphatidylethanolamine; PtdA, phosphatidic acid; PtdG, phosphatidylglycerol; PLy, unassigned PL. Concentrations of glycerophosphocholine (GPC) lipids and their metabolites (µmol/g tissue wet weight, means ± s.d.) are listed in Table 1 with significance levels (p values). The most prominent PL, PtdC, is enhanced in Mecp2-null brain vs. controls, while the PtdC degradation product, lyso-PtdC, is decreased. Phosphocholine (PC) remains constant, while the PC/GPC ratio is increased owing to GPC reduction. The choline (Cho) decrease is of borderline significance, and none of the other PL or PL metabolites are significantly changed.

Discussion

The PL metabolite pattern observed for Mecp2-null mouse brain vs. controls is consistent with a well-established model suggesting a reduced PtdC turnover rate, limiting the ability of cells to grow [6,7], according to the following scheme:

\[\text{PtdC} \rightarrow \text{lyso-PtdC} \rightarrow \text{reduced PtdC turnover} \rightarrow \text{reduced PtdC production} \rightarrow \text{reduced cell growth}\]

Further experiments will reveal to what extent neurons, astrocytes and/or other neural cells are affected by growth reduction due to Mecp2 mutation. These results may open new avenues for the identification of molecular targets for early and efficient pharmacological RS treatment.

References